The Sloan Kettering Cancer Cure Cover-Up

Meet Ralph Moss, Ph.D., former Science Writer and Assistant Director of Public Affairs for one of the most prestigious and well known cancer centers in the world, Memorial Sloan-Kettering Cancer Center, from 1974 to 1977. A very large part of Ralph's job was to write press releases for the hospital about new developments in science regarding cancer, as well as handle calls from people with questions about cancer and various treatments.

 

During the course of writing one of his articles, Mr. Moss interviewed one of the scientists at the hospital, Dr. Kanematsu Sugiura, who was one of the world's premier cancer researchers at the time. The scientist informed Mr. Moss that he had seen repetitive and conclusive positive results over the course of two years of study while studying “amygdalin”, otherwise known as Laetrile, the anticancer ingredient in apricot seeds. Sugiura concluded that Laetrile:

 

1) Inhibited the growth of tumors

2) Stopped the spreading of cancer in mice

3) Relieved pain

4) Acted as a cancer preventative

5) Improved general health

 

After receiving this information Mr. Moss got very excited and planned on writing a big report on it. He then went to his superiors with the good news. It was then that he got, as he puts it in his own words, the “shock of my life”.

 

His superiors demanded that he cease and desist writing the story, saying that Dr. Sugiura's work was invalid, denying that it was real evidence. As the icing on the cake they proceeded to instruct Mr. Moss to write an article and press release for all major news stations stating that amygdalin was worthless for cancer treatment, in other words, they ordered him to lie through his teeth and report the exact opposite of the truth to the American people.

 

“Certainly one story that needs to be told is that of Dr. Kanematsu Sugiura. In 1975, Dr. Sugiura was, and had been for some years, one of the most respected cancer research scientists at Sloan-Kettering. In working with cancerous mice, Dr. Sugiura found that, when he used Laetrile on these mice, seventy-seven per cent of them did not develop a spread of their disease (metastatic carcinoma). He repeated this study over and over for two years. The results were always the same. Dr. Sugiura took his findings to his superiors at Sloan-Kettering, but his study was never published. Instead, Sloan-Kettering published the results of someone else who claimed that he had used Dr. Sugiura's protocol. This 'someone else's study showed that there were no beneficial effects from the use of Laetrile. Dr. Sugiura complained. He was fired. A book was written about all of this entitled The Anatomy of A Cover-up. This book has all the actual results of Dr. Sugiura's work. These results do, indeed, show the benefit of Laetrile. Dr. Sugiura stated in this book, 'It is still my belief that Amygdalin cures metastases.' Amygdalin is, of course, the scientific name for Laetrile.”[1]

 

For the next few months Mr. Moss avoided the subject, and didn't write anything about amygdalin. He decided instead to take that time to conduct an investigation into the people he was working for. Who were they? Why were they asking him to lie? What was their incentive to cover-up such great news concerning cancer treatment? He discovered many interesting facts; their Board of Directors were investors in petrochemicals and CEO's of top drug companies, the Chairman and President of Bristol-Meyers Squibb, the world's biggest seller of chemotherapy drugs was also on the board. Seven of the nine members of the hospital's Institutional Policy Committee had ties to the pharmaceutical industry and the hospital itself invested in the stock of those same drug companies. Directors of the biggest tobacco companies in America, Phillip Morris and RJR Nabisco were also on the Board of Directors at the hospital and six directors also served on the boards of the New York Times, CBS, Warner Communications, Reader's Digest and other mainstream media outlets. In other words, the entire Board of Directors at one of the “world's premier cancer centers” was swimming in corruption and conflicts of interest, to say the very least. I'd love to report that this was an isolated case. I'd love to be able to say that it was only this hospital, but that simply wouldn't be the truth. The truth of the matter is that the entire industry functions that way and those procedures are standard practice. This incident at Sloan-Kettering was just another typical scenario in the Cancer Industry. Business as usual.

 

Mr. Moss wasn't able to avoid the subject of Amygdalin/Laetrile for very long. His secretary's phone was ringing off the hook with people wanting information about it, and again he was told to cover up the truth. He decided, after a conference with his family at home, that he was not willing to lie on behalf of the hospital. In November, 1977 he stood up at a press conference and “blew the whistle on Memorial Sloan-Kettering Cancer Center's suppression of positive results with Laetrile”. When he returned to the office he found that all of his files were padlocked, he was then escorted out of the building by two armed guards.

 

Mr. Moss considers that entire ordeal to have been a stepping stone that led the way to what he was truly meant to do in life; rather than working on the Board of Directors at a place like Sloan-Kettering, he has gone on to write 12 books, 3 documentaries and numerous articles in medical journals concerning complimentary and “alternative” cancer treatments. He eventually wrote a book about his laetrile experience entitled Doctored Results: The Suppression of Laetrile at Sloan-Kettering Institute for Cancer Research. He also runs the website Cancer Decisions: The Moss Reports which can be found at CancerDecisions.com.